Evidence map›Paper›PMID 38504538›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2024

Protective effect of modified Huangqi Chifeng decoction on immunoglobulin A nephropathy through toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B signaling pathway.

L I Liusheng, Zhao Mingming, Chang Meiying, S I Yuan, Zhao Jinning, Yang Bin, Zhang Yu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

L I LiushengDepartment of Oncology, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing 100039, China.
Zhao MingmingDepartment of Nephropathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Chang MeiyingDepartment of Nephropathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
S I YuanDepartment of Nephropathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Zhao JinningDepartment of Experimental Research Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Yang BinDepartment of Pathology Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Zhang YuDepartment of Nephropathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Guangzhou University of Chinese Medicine · CNBeijing Hospital · CN

Funding

Joint Innovation Fundation of JIICM: Health Management of Chronic Kidney Disease Based on Integrated Traditional Chinese And Western Medicine 2021IR009Natural Science Foundation-funded Project: the Mechanism of Modified Huangqi Chifeng Decoction Protect Damaged Podocyte via Cross-Talking of PI3K/AKT/mTOR and AMPK/mTOR/ULK1 Signaling Pathway Regulate Autophapy 81873300The Beijing Municipal of Science and Technology Major Project: Evaluation of Clinical Efficacy of Modified Huangqi Chifeng Decoction in Treating Proteinuria in IgA Nephropathy Based on "Deficiency-Wind-Blood-Stasis-Toxicity" Mechanism in Chinese Medicine Z191100006619063The Central Public-interest Scientific Institution Basal Research Fund of the China Academy of Chinese Medical Sciences: Comprehensive Evaluation of Clinical efficacy of Modified Huangqi Chifeng Decoction on IgA Nephropathy ZZ11-023
6 · The paper itself

Abstract

objectiveTo examine the nephroprotective mechanism of modified Huangqi Chifeng decoction (, MHCD) in immunoglobulin A nephropathy (IgAN) rats.

methodsTo establish the IgAN rat model, the bovine serum albumin, lipopolysaccharide, and carbon tetrachloride 4 method was employed. The rats were then randomly assigned to the control, model, telmisartan, and high-, medium-, and low-dose MHCD groups, and were administered the respective treatments via intragastric administration for 8 weeks. The levels of 24-h urinary protein, serum creatinine (CRE), and blood urea nitrogen (BUN) were measured in each group. Pathological alterations were detected. IgA deposition was visualized through the use of immunofluorescence staining. The ultrastructure of the kidney was observed using a transmission electron microscope. The expression levels of interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-β1 (TGF-β1) were examined by immunohistochemistry and quantitative polymerase chain reaction. Levels of toll-like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and nuclear factor-kappa B (NF-κB) P65, were examined by immunohistochemistry, Western blotting, and quantitative polymerase chain reaction.

resultsThe 24-h urine protein level in each group increased significantly at week 6, and worsen from then on. But this process can be reversed by treatments of telmisartan, and high-, medium-, and low-dose of MHCD, and these treatments did not affect renal function. Telmisartan, and high-, and medium-dose of MHCD reduced IgA deposition. Renal histopathology demonstrated the protective effect of high-, medium-, and low-dose of MHCD against kidney injury. The expression levels of MCP-1, IL-6, and TGF-β1 in kidney tissues were downregulated by low, medium and high doses of MHCD treatment. Additionally, treatment of low, medium and high doses of MHCD decreased the protein and mRNA levels of TLR4, MyD88, and NF-κB.

conclusionsMHCD exerted nephroprotective effects on IgAN rats, and MHCD regulated the expressions of key targets in TLR4/MyD88/NF-κB signaling pathway, thereby alleviating renal inflammation by inhibiting MCP-1, IL-6 expressions, and ameliorating renal fibrosis by inhibiting TGF-β1 expression.

Indexed as

Astragalus propinquusDrugs, Chinese HerbalGlomerulonephritis, IGAAnimalsImmunoglobulin AInterleukin-6Myeloid Differentiation Factor 88NF-kappa BRatsSignal TransductionTelmisartanToll-Like Receptor 4Transforming Growth Factor beta1Drugs, Chinese HerbalHuang QiImmunoglobulin AInterleukin-6Myeloid Differentiation Factor 88NF-kappa BTelmisartanToll-Like Receptor 4Transforming Growth Factor beta1glomerulonephritis, IGAinflammationmodified Huangqi Chifeng decoctionmyeloid differentiation factor 88NF-kappa Brenal fibrosissignal transductiontoll-like receptor 4

Identifiers

PMID38504538
PMCPMC10927408
OpenAlexW4394738967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.